ÜbersichtsarbeitOpen Access
VMAT2 Inhibitors for Tardive Dyskinesia: What Psychiatrists Should Know
Focus · 2026-04 · 24 (2) · 159-167
DOI: 10.1176/appi.focus.20250044 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Focus, 2026-04. Verfasst von Arthur N Westover und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
AntipsychoticsPharmacotherapyTardive DyskinesiaVesicular Monoamine Transporter 2 Inhibitorsdeutetrabenazinevalbenazine
Autor:innen und Institutionen
- Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas.
- Center for Depression Research and Clinical Care, Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas.
- Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas.
Zitieren
APA
Westover, A. N., Perez, J., Patel, Z., & Jha, M. K. (2026). VMAT2 Inhibitors for Tardive Dyskinesia: What Psychiatrists Should Know. Focus, 24(2), 159-167. https://doi.org/10.1176/appi.focus.20250044
Vancouver
Westover AN, Perez J, Patel Z, Jha MK. VMAT2 Inhibitors for Tardive Dyskinesia: What Psychiatrists Should Know. Focus. 2026;24(2):159-167. doi:10.1176/appi.focus.20250044
BibTeX
@article{Westover2026,
author = {Westover, Arthur N and Perez, Jennifer and Patel, Zena and Jha, Manish K},
title = {VMAT2 Inhibitors for Tardive Dyskinesia: What Psychiatrists Should Know},
journal = {Focus},
year = {2026},
volume = {24},
number = {2},
pages = {159--167},
doi = {10.1176/appi.focus.20250044}
}
EUVIMED